This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revision | Next revisionBoth sides next revision | ||
home:diseases:celiac [03.13.2019] – [recent research] sallieq | home:diseases:celiac [07.12.2019] – [recent research] sallieq | ||
---|---|---|---|
Line 66: | Line 66: | ||
Findings suggest that neither olmesartan nor other ARBs were associated with diarrhea among patients undergoing endoscopy. The spruelike enteropathy recently associated with olmesartan is likely a rare adverse effect and milder presentations are unlikely. | Findings suggest that neither olmesartan nor other ARBs were associated with diarrhea among patients undergoing endoscopy. The spruelike enteropathy recently associated with olmesartan is likely a rare adverse effect and milder presentations are unlikely. | ||
- | In a methotrexate-induced | + | 2018 data show that OLM is an Nrf2 activator, NFkB inhibitor and apoptosis inhibitor in an experimental |
+ | (({{pubmed> | ||
{{tag> | {{tag> |